Table 2.
Characteristics of 143 patients with pheochromocytoma/paraganglioma (PCC/PGL)
| Characteristics | N, or mean |
|---|---|
| Mean age, years ± SD | 47.6 ± 15.4 |
| Gender, n (%) | |
| Female | 82 (57.3) |
| Male | 61 (42.7) |
| Race, n (%) | |
| African American | 35 (24.5) |
| Caucasian | 80 (55.9) |
| Other | 28 (19.6) |
| Germline susceptibility gene mutation, n (%) | |
| No mutation | 53 (37.1) |
| Not tested | 50 (35.0) |
| NF1 | 9 (6.3) |
| RET | 6 (4.2) |
| SDHB | 11 (7.7) |
| SDHD | 5 (3.5) |
| Variant of undetermined significancea | 2 (1.4) |
| VHL | 7 (4.9) |
| Tumor type, n (%) | |
| Pheochromocytoma | 106 (74.1%) |
| Paraganglioma | 37 (25.9%) |
| Dominant secreted catecholamine, n (%) | |
| Epinephrine | 46 (32.2%) |
| Norepinephrine | 89 (62.2%) |
| Unknown | 8 (5.6%) |
Abbreviations: SD, standard deviation; NF1, Neurofibromatosis 1; RET, rearranged during transfection; SDHB, Succinate dehydrogenase subunit B; SDHD, Succinate dehydrogenase subunit D; VHL, von Hippel Lindau.
a SDHD c.T320C; p.L107P; TMEM127 c0.409 + 7C>T.